Actions for Biomarkers of neuroinflammation : proceedings of a workshop

Email RIS file
Bookmark
Report an Issue

Biomarkers of neuroinflammation : proceedings of a workshop / Lisa Bain, Noam I. Keren, and Sheena M. Posey Norris, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Health and Medicine Division

Author
Bain, Lisa J.
Published
Washington, DC : The National Academies Press, [2018]
Physical Description
1 online resource (1 PDF file (xi , 77 pages)) : illustrations
Additional Creators
Keren, Noam I., Norris, Sheena M. Posey, National Academies of Sciences, Engineering, and Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders, and Biomarkers of Inflammation (Workshop) (2017 : Washington, D.C.)
Access Online

Availability

I Want It
I Want It

Finding items...

Series
Contents
Introduction and overview -- Biomarkers of neuroinflammation: challenges and potential opportunities -- State of the science of neuroinflammation in central nervous system disorders -- Neuroinflammation in disease -- Neuroimaging biomarkers: current initiatives and opportunities -- Cerebrospinal fluid and other fluid biomarkers: current initiatives and opportunities -- Potential mechanisms for moving forward -- Appendixes.
Summary
Neuroinflammation is a burgeoning area of interest in academia and biopharma, with a broadly acknowledged role in many central nervous system (CNS) disorders. However, there is little agreement on the pathophysiological mechanisms that underlie the manifestations of neuroinflammation in the CNS compartment and how neuroinflammation operates as a driver and also as a consequence of disease in the brain. Moreover, another unclear area is how to translate increased understanding of the mechanisms that underlie neuroinflammation and its manifestations in the CNS to therapeutics. To address these gaps in understanding mechanisms and how to translate that understanding into therapeutics, the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop on March 20-21, 2017, bringing together key leaders in the field from industry, academia, and governmental agencies to explore the role and mechanisms of neuroinflammation in a variety of CNS diseases. The workshop also considered strategies to advance the identification and validation of biomarkers of neuroinflammation that could accelerate development of therapies, bringing much-needed treatments to patients with disorders ranging from neuroinflammatory diseases such as multiple sclerosis (MS) to neuropsychiatric disorders such as depression. This publication summarizes the presentations and discussions from the workshop.
Subject(s)
Genre(s)
ISBN
9780309463669
0309463661
9780309463683 (electronic bk.)
0309463688 (electronic bk.)
9780309463652
0309463653
Bibliography Note
Includes bibliographical references.
Funding Information
This activity was supported by contracts between the National Academy of Sciences and the Alzheimer's Association; Brain Canada Foundation; Cohen Veterans Bioscience; the Department of Health and Human Services' Food and Drug Administration (5R13FD005362-02) and National Institutes of Health (NIH) (HHSN26300089 [Under Master Base #DHHS-10002880]) through the National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (VA240-14-C-0057); Eli Lilly and Company; Foundation for the National Institutes of Health; The Gatsby Charitable Foundation; George and Anne Ryan Institute for Neuroscience at The University of Rhode Island; Janssen Research & Development, LLC; Lundbeck Research USA; Merck Research Laboratories; The Michael J. Fox Foundation for Parkinson's Research; National Multiple Sclerosis Society; National Science Foundation (BCS-1064270); One Mind; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; Society for Neuroscience; and Takeda Development Center Americas, Inc. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for this project.
View MARC record | catkey: 43281102